Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[RU 486--death hides behind this formula].

I von Brauchitsch

    Wiener Medizinische Wochenschrift (1946)
    |January 1, 1992
    PubMed
    Summary

    The hormone drug RU 486 offers a new method for early-term abortions and contraception. This pharmaceutical innovation presents potential for family planning, especially in developing nations.

    Related Experiment Videos

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    [Legal protection of the fetus in West Germany].

    Wiener medizinische Wochenschrift (1946)·1992
    Same author

    [AIDS and the law. Does the state neglect its protective function?].

    Diskussionsforum medizinische Ethik·1991
    See all related articles

    Area of Science:

    • Pharmacology
    • Reproductive Health

    Context:

    • The introduction of RU 486 (mifepristone) represents a significant advancement in medical abortion.
    • Availability in France, Great Britain, and China highlights its international presence.

    Purpose:

    • To detail the mechanism and application of RU 486 as an early-term abortion agent.
    • To explore its potential as a contraceptive and for family planning in resource-limited settings.

    Summary:

    • RU 486, a hormone drug, induces artificial miscarriage up to the 49th day of pregnancy.
    • Its development by Roussel-Uclaf offers new possibilities for reproductive health management.

    Impact:

    • Potential to reshape family planning strategies, particularly in Third World countries.
    • Regulatory approval in Germany is contingent upon new legislation, misuse prevention, and demonstrated need.